



NDA 22134/S-001

**SUPPLEMENT APPROVAL**

Allergan, Inc.  
Attention: Bosco D'Sa, PhD  
Senior Manager, Regulatory Affairs  
2525 Dupont Dr., P.O. Box 19534  
Irvine, CA 92623-0534

Dear Dr. D'Sa:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 31, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LASTACRAFT (alcaftadine ophthalmic solution), 0.25%.

We acknowledge receipt of your amendment dated June 19, 2014. This submission constituted a complete response to our Complete Response letter dated March 9, 2014.

This Prior Approval" supplemental new drug application provides for revisions to the DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DESCRIPTION, and PATIENT COUNSELING INFORMATION sections of the package insert. It also provides for the replacement of Vistakon specific manufacturing information with Allergan specific manufacturing information at the end of the package insert following Section 17.3.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Chief, Project Management Staff at 301-796-0763.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, MD  
Deputy Director  
Division of Transplant and Ophthalmology Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE(S): Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

WILEY A CHAMBERS  
12/04/2014